
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$314.19M
Market Cap
-
P/E Ratio
-2.53
EPS
$19.58
52 Week High
$4.88
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$16K |
| Total Revenue | $0 |
| Cost Of Revenue | $16K |
| Costof Goods And Services Sold | $16K |
| Operating Income | -$23M |
| Selling General And Administrative | $5.3M |
| Research And Development | $17M |
| Operating Expenses | $23M |
| Investment Income Net | - |
| Net Interest Income | $2.4M |
| Interest Income | $2.4M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $16K |
| Income Before Tax | -$21M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$21M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$23M |
| Ebitda | -$23M |
| Net Income | -$21M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$16K |
| Total Revenue | $0 |
| Cost Of Revenue | $16K |
| Costof Goods And Services Sold | $16K |
| Operating Income | -$23M |
| Selling General And Administrative | $5.3M |
| Research And Development | $17M |
| Operating Expenses | $23M |
| Investment Income Net | - |
| Net Interest Income | $2.4M |
| Interest Income | $2.4M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $16K |
| Income Before Tax | -$21M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$21M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$23M |
| Ebitda | -$23M |
| Net Income | -$21M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of innovative small-molecule therapies aimed at activating innate homeostatic pathways to effectively manage metabolic diseases. The company's robust research and development efforts underscore its commitment to addressing significant unmet medical needs, positioning Aardvark for substantial contributions to the biopharmaceutical sector. With a strong pipeline and a focus on rigorous clinical trials, Aardvark is poised to potentially transform the treatment landscape in its targeted therapeutic areas.